BUSINESSglobal
New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b - Endpoints News
Single source
Updated 2 hours ago
First seen March 18, 2026 10:51:14Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2b Endpoints News R1 zooms out of stealth with $77.5M series A to advance chronic kidney disease treatment Fierce Biotech R1 starts up with $78M, aiming for a better kidney drug BioPharma Dive Biotechnology Start-Up Partners with Alebund Pharmaceuticals to Develop New Therapy for Hyperphosphatemia in CKD Patients geneonline.com Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 Yahoo Finance